Pharmacokinetics of Lamivudine at Two Different Doses
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to measure the pharmacokinetics (how a drug is absorbed,
distributed and eliminated from the body) of lamivudine (3TC) and its active component after
3TC is given at two different doses, 300mg and 150mg once daily.